Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
Abstract This study used linked, routinely-collected datasets to explore incidence, clinical characteristics and outcomes of prostate cancer (PC) patients who experience a rise in prostate-specific antigen (PSA) levels despite androgen deprivation therapy (ADT), without evidence of metastases in the...
Guardado en:
Autores principales: | Peter Arnold, Maria Cristina Penaloza-Ramos, Lola Adedokun, Sarah Rees, Mohamed Lockhat, Lisa Spary, Alan Watkins, Vincent Gnanapragasam, Simon J. Crabb |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/77469af6cc4b4e7585b202b8548a0ce0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
por: Nikolai A. Ognerubov
Publicado: (2021) -
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer
por: Jingsong Zhang, et al.
Publicado: (2017) -
Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma
por: Faiza Naseer, et al.
Publicado: (2021) -
Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
por: Caffo O, et al.
Publicado: (2016) -
PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
por: A. Franza, et al.
Publicado: (2022)